Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)‘s stock had its “buy” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Thursday. They presently have a $50.00 target price on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 102.43% from the company’s previous close.

Several other analysts have also commented on the stock. HC Wainwright increased their price target on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, July 18th. BidaskClub lowered shares of Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Saturday, August 5th. Raymond James Financial, Inc. reissued a “strong-buy” rating and set a $36.00 price target on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. Finally, ValuEngine lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $37.44.

Paratek Pharmaceuticals (NASDAQ PRTK) opened at 24.70 on Thursday. The firm has a 50-day moving average of $23.26 and a 200 day moving average of $21.71. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $29.00. The stock’s market capitalization is $685.70 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. The firm had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $7.50 million.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Reiterates “Buy” Rating for Paratek Pharmaceuticals, Inc. (PRTK)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/23/cantor-fitzgerald-reiterates-buy-rating-for-paratek-pharmaceuticals-inc-prtk-2.html.

In related news, CFO Douglas W. Pagan sold 4,139 shares of the stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $97,597.62. Following the completion of the transaction, the chief financial officer now directly owns 60,000 shares of the company’s stock, valued at approximately $1,414,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Adam Woodrow sold 3,800 shares of the stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total transaction of $89,604.00. Following the completion of the transaction, the vice president now directly owns 69,500 shares of the company’s stock, valued at $1,638,810. The disclosure for this sale can be found here. Insiders sold a total of 17,365 shares of company stock valued at $409,467 over the last ninety days. 4.90% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in PRTK. C WorldWide Group Holding A S raised its position in shares of Paratek Pharmaceuticals by 449.3% in the 2nd quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock valued at $10,590,000 after purchasing an additional 359,400 shares during the last quarter. Pictet Asset Management Ltd. purchased a new position in shares of Paratek Pharmaceuticals in the 2nd quarter valued at approximately $6,957,000. State Street Corp raised its position in shares of Paratek Pharmaceuticals by 112.3% in the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock valued at $14,850,000 after purchasing an additional 325,856 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Paratek Pharmaceuticals by 275.9% in the 1st quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock valued at $7,979,000 after purchasing an additional 304,249 shares during the last quarter. Finally, Numeric Investors LLC purchased a new position in shares of Paratek Pharmaceuticals in the 2nd quarter valued at approximately $6,449,000. 82.33% of the stock is owned by hedge funds and other institutional investors.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.